tbuckley/cabot-search huggingface dataset:
Reanalysis of Bell, Weinberg, and Hammersmith's data on birth order, sibling sex ratio, and parental age in homosexual men
Authors: R Blanchard, K J Zucker
Journal: American Journal of Psychiatry (1994)

The authors compared parental age, birth order, and sex ratio of siblings for 575 homosexual men and 284 heterosexual men, matched on age and education. They were originally part of Bell, Weinberg, and Hammersmith's large-scale study of male and female homosexuality. The results confirmed the previous findings that homosexual men have older fathers and later births than do heterosexual men but not the finding that homosexual men have larger proportions of brothers. The collective findings suggest that birth order is perhaps the single most reliable demographic difference between homosexual and heterosexual men.
Incidence and Clinical Relevance of TEL/AML1 Fusion Genes in Children With Acute Lymphoblastic Leukemia Enrolled in the German and Italian Multicenter Therapy Trials
Authors: Arndt Borkhardt, Giovanni Cazzaniga, Susanne Viehmann, Maria Grazia Valsecchi, Wolf Dieter Ludwig, Linda Burci, Silvia Mangioni, Martin Schrappe, Hansjörg Riehm, Fritz Lampert, Giuseppe Basso, Giuseppe Masera, Jochen Harbott, Andrea Biondi
Journal: Blood (1997)
Abstract 1193: Mast Cell Activation Promotes Leukocyte Recruitment And Adhesion To The Atherosclerotic Plaque
Authors: Ilze Bot, Saskia C de Jager, Alma Zernecke, Christian Weber, Theo J van Berkel, Erik A Biessen
Journal: Circulation (2007)

Activated mast cells have been identified in the perivascular tissue of human coronary artery plaques. As mast cells have been described to release a whole array of chemokines including interleukin 8 (IL-8) and MIP1 α, we propose that activated mast cells play a pivotal role in leukocyte recruitment at advanced stages of atherosclerotic plaque development. Peritoneal mast cells of either C57Bl/6 or mast cell deficient Kit(W −sh /W −sh ) mice were activated by injection of compound 48/80 (1.2 mg/kg). Interestingly, mast cell activation led to a massive neutrophil influx into the peritoneal cavity at 3 hours after activation (controls: 1 ± 0.7*10 4 Gr1 + -neutrophils/ml up to 8 ± 0.2*10 4 Gr1 + neutrophils/ml at 3 hours after activation, *P&lt;0.05), while neutrophil numbers in Kit(W −sh /W −sh ) mice were not affected by compound 48/80 administration. Moreover, increased levels of CXCR2 + Gr1 + neutrophils (t=0: 0.55 ± 0.07% versus t=3 hours: 1.00 ± 0.12%, *P&lt;0.05) were observed after mast cell activation. Next, we investigated whether mast cell activation also translated in induced leukocyte adhesion to advanced atherosclerotic plaques. Adventitial mast cells of advanced collar aided carotid artery plaques were activated by local application of a dinitrophenyl-BSA (DNP) challenge in ApoE −/− mice. Three days later, the carotid artery segments carrying the plaques were isolated and perfused ex vivo with rhodamine labeled leukocytes, showing a dramatically increased number of adherent leukocytes after mast cell activation (49 ± 6 versus 19 ± 4 leukocytes/microscopic field for DNP versus control plaques, respectively, **P&lt;0.001). Strikingly, antibody blockade of either the CXCR2 or VCAM-1 receptor VLA-4 on labeled leukocytes completely inhibited leukocyte adhesion to the atherosclerotic plaque (*P&lt;0.05), while blockade of CCR1, -3 and -5 with Met-RANTES had no effect. In conclusion, our data suggest that chemokines such as IL-8 released from activated perivascular mast cells induce leukocyte recruitment and adhesion to the atherosclerotic plaque, aggravating the ongoing inflammatory response and thus effecting plaque destabilization. We propose that mast cell stabilization could be a new therapeutic approach in the prevention of acute coronary syndromes.
Long Term Follow-Up After Imatinib Cessation For Patients Indeep Molecular Response: The Update Results Of The STIM1 Study
Authors: Francois-Xavier Mahon, Delphine Rea, Joelle Guilhot, Francois Guilhot, Françoise Huguet, Franck E. Nicolini, Laurence Legros, Aude Charbonnier, Agnès Guerci, Bruno R. Varet, Gabriel Etienne, Josy Reiffers, Philippe Rousselot
Journal: Blood (2013)
Abstract 10610: Cxcr4 Overexpression Promotes Mitochondrial Function to Protect Against Ischemia-reperfusion-induced Cardiomyocyte Death
Authors: Wen-feng Cai, Kai Kang, Wei Huang, Jia-Liang Liang, Yu-Liang Feng, Yu-Hua Wang, De-Hua Chang, Zhi-Li Wen, Mei-Feng Xu, Ronald W Millard, Muhammad Ashraf, Yi-Gang Wang
Journal: Circulation (2013)

Background and Objective:  The chemokine (C-X-C motif) receptor 4 (CXCR4) is expressed on native cardiomyocytes and can decrease isolated cardiomyocyte contractility. Here, we examine the role of CXCR4 in cardiomyocyte response to ischemia-reperfusion (I/R) injury.   Methods and Results:  Isolated adult rat ventricular cardiomyocytes were subjected to hypoxia/re-oxygenation (H/R) to simulate ischemia/reperfusion (I/R) injury. The decrease in CXCR4 expression by 35%, 55% and 77% at 4, 7 and 9 hours after re-oxygenation was associated with dysfunctional energy metabolism indicated by an increased ADP/ATP ratio. To examine a possible nexus, we investigated whether CXCR4 over-expression (OE) can prevent bio-energetic disruption-associated cell death using adenoviral infection of cardiomyocytes with CXCR4 encoding-gene or non-translated nucleotide sequence (Control). Indeed, there was 2.5-fold increase in CXCR4 expression level in cardiomyocytes post CXCR4-adenovirus transduction. Although the same extent of H/R-provoked cytosolic calcium overload (~1.3-fold) was measured (Fig. 1A), the hydrogen-peroxide-induced the decay of mitochondrial membrane potential (Δψm) was suppressed in CXCR4 OE group compared with Control group (Fig. 1B). Despite calcium overload, mitochondrial swelling was significantly attenuated in CXCR4 group, implicating that CXCR4 OE prevents permeability transition pore (mPTP) opening (Fig. 1C). Consequently, in the presence of H/R, mitochondrial dysfunction was mitigated (Fig. 1D) and cardiomyocyte death was decreased to 65% in the CXCR4 OE group, compared with the control group.   Conclusion:  While ATP production and CXCR4 expression in cardiomyocytes are decreased by ischemia-reperfusion injury, CXCR4 OE can alleviate mitochondrial swelling and prevent energy disruption to improve cardiomyocyte survival.
Estimating the Global Burden of Foodborne Diseases - a collaborative effort
Authors: T Kuchenmüller, S Hird, C Stein, P Kramarz, A Nanda, A H Havelaar
Journal: Eurosurveillance (2009)

Illness and death from diseases caused by unsafe food are a constant threat to public health security as well as socio-economic development throughout the world. The full extent of the burden and cost of foodborne diseases associated with pathogenic bacterial, viral and parasitic microorganisms, and food contaminated by chemicals is still unknown but is thought to be substantial. The World Health Organization (WHO) Initiative to estimate the global burden of foodborne diseases aims to fill the current data gap and respond to the increasing global interest in health information. Collaborative efforts are required to achieve the ambitious task of assessing the foodborne disease burden from all causes worldwide. Recognising the need to join forces, the WHO Initiative has assembled an alliance of stakeholders which share and support the Initiative's vision, intended objectives and outcomes. One important collaborator is the European Centre for Disease Prevention and Control (ECDC) which has embarked on a burden of disease study covering at least 18 foodborne diseases in nearly 30 countries.
Corticosteroids in acute respiratory distress syndrome: meta-analysis
Authors: Nick Dunn
Journal: BMJ (2008)

Nick Dunn explains a study that uses Bayesian methods ### This month's paper “Corticosteroids in the prevention and treatment of acute respiratory distress syndrome (ARDS) in adults: meta-analysis” by John Victor Peter and colleagues ( BMJ 2008;336:1006-9; www.bmj.com/cgi/content/abstract/336/7651/1006). You can read the paper and see responses to it by going to student.bmj.com and clicking on the link. #### Abstract
Abstract 16643: Very Low LDL Cholesterol Level Below 50mg/dL is Not Harmful for Patients Underwent Percutaneous Coronary Intervention in Drug Eluting Stent Era
Authors: Min-Kyu Kang, Jung Yeon Chin, Jung Yeon Yi, Byung-Hee Hwang, Tae-Seok Kim, Chan Joon Kim, Ki-Bae Seung, Wook Sung Chung, Kiyuk Chang, Pum Joon Kim, Hun-Jun Park, Yoon-Seok Koh, Suk Min Seo, Eun Ho Choo, Soe Hee Ann
Journal: Circulation (2011)

Introduction There has been the paucity of data for the safety of very low LDL-cholesterol level below 50 mg/dL in patients with coronary artery disease who underwent percutaneous coronary intervention. Hypothesis Very low LDL-C level may be safe in patients underwent PCI in terms of major adverse cardiac event including death, nonfatal myocardial infarction, stroke or revascularization of any cause. Methods We analyzed a total 9,292 consecutive patients who underwent PCI using drug eluting stent from January 2004 to December 2009. Among these, 2704 subjects who had initial and follow-up lipid panel and attained low LDL-cholesterol (LDL-C&lt;100mg/dL) with statin therapy were enrolled. Median follow up period was 28.3 months (interquartile range 15.1, 41.5 months). Laboratory study was performed at the time of index drug-eluting stent implantation and at the outpatient visit between three and twelve months later. We categorized patients into three groups based on the follow-up LDL-cholesterol level : &lt;50, 50 to 70, 71 to 100 mg/dL(n=399, 1028, 1277, respectively). We compared major adverse cardiac events including all-cause death, nonfatal myocardial infarction, stroke and revascularization of any cause according to the follow up LDL-cholesterol group. Results Multivariable Cox regression analysis revealed that in the patients with well controlled follow up LDL-C level (LDL&lt;100 mg/dL), multivessel disease, presence of angiographic AHA/B2C lesion were strongly associated with increase in a hazard ratio of a composite of death, myocardial infarction, strtoke and revascularization of any cause. But LDL-C was not associated with the occurrence of MACEs. (Table 1.) Conclusions In patients who underwent PCI with DES and well controlled LDL level, cholesterol paradox is not observed. It may be safe in patients with very low LDL-C level below 50 mg/dL in spite of continuous use of statin in terms of MACEs. Keywords lipoprotein, hyperlipidemia, coronary heart disease, PCI
Abstract 3940: Direct Myocardial Actions of Advanced Glycation Endproducts (AGEs) on Cytosolic Calcium Transients Mediated Through Reactive Oxygen Species
Authors: Zeinab Hegab, Stephen Gibbons, Tamer Mohamed, Mohamed Shaheen, Celine Schelcher, Delvac Oceandy, Elizabeth Cartwright, Ludwig Neyses, Mamas Mamas
Journal: Circulation (2009)

Advanced Glycation End products (AGEs) are formed through non enzymatic glycation of proteins in conditions such as diabetes and may influence cellular function through actions on cell surface rece...
Abstract 3367: Metformin as a Cardioprotective Agent in Heart Transplantation Decreases Ischemia-Reperfusion Injury and Chronic Rejection
Authors: Joshua J Troke, Satoshi Itoh, Naoyuki Kimura, Jeffrey B Velotta, Hideyuki Yoshioka, Kuniyasu Niizuma, Pak Hoo Chan, Robert C Robbins, Michael P Fischbein
Journal: Circulation (2009)
<i>CYP2C19</i>Genotype and Outcomes of Clopidogrel Treatment
Authors: Tobias Geisler, Boris Bigalke, Matthias Schwab
Journal: New England Journal of Medicine (2011)

To the Editor: Pare et al. (Oct. 28 issue)1 report that among genotyped patients with acute coronary syndromes or atrial fibrillation, the effects of clopidogrel were consistent irrespective of the loss-of-function CYP2C19*2 allele, whereas gain-offunction CYP2C19*17 carriers with acute coronary syndromes benefited. Unlike these predominantly noninterventionally treated patients, loss-of-function genotypes may play a role in high-risk groups throughout the peri-interventional phase in patients with acute coronary syndromes.2 Current predictive models including the CYP2C19*2 polymorphism and nongenetic risk factors still explain only about 12% of variability of clopidogrel responsiveness,3,4 but they may have an increasing role after consideration of additional pharmacogenetic and clinical variables.5 A conclusive judgment about the relationship between CYP2C19 variants and the efficacy and safety of clopidogrel may be premature. A systematic investigation of cisand trans-genetic determinants with the use of new interactome models is needed. This investigation would involve a genomewide association study or a next-generation sequencing approach.
Increased Risk of Colorectal Cancer Among Family Members of All Ages, Regardless of Age of Index Case at Diagnosis
Authors: N. Jewel Samadder, Ken Robert Smith, Heidi Hanson, Richard Pimentel, Jathine Wong, Kenneth Boucher, Dennis Ahnen, Harminder Singh, Cornelia M. Ulrich, Randall W. Burt, Karen Curtin
Journal: Clinical Gastroenterology and Hepatology (2015)
Abstract 16854: Arterial Determinants of Time-varying Myocardial Stress in Humans
Authors: Julio A Chirinos, Ernst R Rietzschel, Thierry C Gillebert, Amit Gupta, Marc L De Buyzere, Dirk De Bacquer, Martin St. John Sutton, Patrick Segers, Asklepios Investigators
Journal: Circulation (2010)

Background:  Myocardial and arterial load are time-varying phenomena. Despite its importance in myocardial biology and function, the arterial properties that determine time-resolved myocardial wall stress have not been directly investigated.   Methods:  We studied 1215 adults enrolled in the population-based Asklepios study. Time-resolved central pressure and flow were measured with carotid tonometry and Doppler echocardiography. Time-resolved short- and long-axis LV geometry was measured with speckle tracking echocardiography. Using custom-designed software, we computed arterial load, circumferential (CWS) and longitudinal (LWS) wall stress (Regen method) using time-resolved measurements.   Results:  For any given end-diastolic LV cavity size and wall thickness and any given cardiac output, peak CWS correlated directly with systemic vascular resistance (SVR; Beta weight=1.07; P   Conclusions:  Different arterial properties have selective effects on time-resolved myocardial wall stress which are not apparent from single-time-point measurements. Women appear to demonstrate less efficient myocardial-ventricular-arterial coupling (higher time-varying stress for a given output) independently of various arterial properties and end-diastolic LV geometry. These observations could provide insight into the well known differential susceptibility of women to heart failure with preserved ejection fraction.
The Electrocardiogram Predicts One-Year Outcome of Patients With Unstable Angina and Non–Q Wave Myocardial Infarction: Results of the TIMI III Registry ECG Ancillary Study fn1fn1The TIMI III Clinical Centers are supported by Grant R01-HL42311 and the Data Coordinating Center by Grant R01-HL42428 from the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland. Additional support was supplied by Genentech, Inc., South San Francisco, California.
Authors: Christopher P. Cannon, Carolyn H. McCabe, Peter H. Stone, William J. Rogers, Mark Schactman, Bruce W. Thompson, Douglas J. Pearce, Daniel J. Diver, Catherine Kells, Ted Feldman, Marcus Williams, Robert S. Gibson, Marvin W. Kronenberg, Leonard I. Ganz, H.Vernon Anderson, Eugene Braunwald
Journal: Journal of the American College of Cardiology (1997)
Malignant hyperthermia and ECT
Authors: O F Yacoub, D H Morrow
Journal: American Journal of Psychiatry (1986)

The malignant hyperthermia syndrome is a rare hypermetabolic state that occurs in patients after the administration of certain drugs, most frequently anesthetics and/or succinylcholine. In view of the widespread use of succinylcholine to induce muscle relaxation prior to ECT, it is important that the individual who administers succinylcholine in this setting be familiar with the syndrome and its treatment. This report reviews what is known about malignant hyperthermia and proposes a course of action when the syndrome occurs in a patient undergoing ECT or a patient with known susceptibility to malignant hyperthermia needs ECT.
Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders
Authors: J Biederman, J Newcorn, S Sprich
Journal: American Journal of Psychiatry (1991)

Attention deficit hyperactivity disorder is a heterogeneous disorder of unknown etiology. Little is known about the comorbidity of this disorder with disorders other than conduct. Therefore, the authors made a systematic search of the psychiatric and psychological literature for empirical studies dealing with the comorbidity of attention deficit hyperactivity disorder with other disorders.The search terms included hyperactivity, hyperkinesis, attention deficit disorder, and attention deficit hyperactivity disorder, cross-referenced with antisocial disorder (aggression, conduct disorder, antisocial disorder), depression (depression, mania, depressive disorder, bipolar), anxiety (anxiety disorder, anxiety), learning problems (learning, learning disability, academic achievement), substance abuse (alcoholism, drug abuse), mental retardation, and Tourette's disorder.The literature supports considerable comorbidity of attention deficit hyperactivity disorder with conduct disorder, oppositional defiant disorder, mood disorders, anxiety disorders, learning disabilities, and other disorders, such as mental retardation, Tourette's syndrome, and borderline personality disorder.Subgroups of children with attention deficit hyperactivity disorder might be delineated on the basis of the disorder's comorbidity with other disorders. These subgroups may have differing risk factors, clinical courses, and pharmacological responses. Thus, their proper identification may lead to refinements in preventive and treatment strategies. Investigation of these issues should help to clarify the etiology, course, and outcome of attention deficit hyperactivity disorder.
Attention deficit hyperactivity disorder
Authors: F. Levy
Journal: BMJ (1997)

A syndrome that was described by the ancient Greeks and has been widely observed by physicians since then is likely to have considerable face validity, but there continues to be disagreement about the diagnosis, cause, prevalence, and treatment of attention deficit hyperactivity disorder.1 From the beginning of this century the concept of the condition has evolved from it being a biologically based disorder of behaviour control, from a condition with minimal brain dysfunction, to a disorder characterised by a deficit of attention.2 The main controversy now is about how to treat the condition.

The past 20 years have seen the development of diagnostic criteria in both Britain and America. In 1981 the criteria of the Diagnostic and Statistical Manual version III (DSM-III) departed from those of the International Classification of Diseases ninth edition (ICD-9) in creating subtypes of attention deficit disorder with and without hyperactivity. Meanwhile, the ICD-9 continued to emphasise “pervasive hyperactivity” as the hallmark of …
A Phase III Study of Subconjunctival Human Anti–Transforming Growth Factor β2 Monoclonal Antibody (CAT-152) to Prevent Scarring after First-Time Trabeculectomy
Authors: Peng Khaw, Franz Grehn, Gábor Holló, Barry Overton, Rosamund Wilson, Roger Vogel, Zaid Smith
Journal: Ophthalmology (2007)
Abstract 3231: Recombinant Periostin Peptide Improves Myocardial Function and Decreases Scar Size in a Preclinical Infarct Model
Authors: Dennis Ladage, Yoshiaki Kawase, Scott Shapiro, Shima Arab, Mario J Garcia, Roger J Hajjar, Bernhard Kuhn
Journal: Circulation (2009)

Replacing lost cardiomyocytes using regenerative strategies would offer a revolutionary strategy for the treatment of heart failure. We previously demonstrated that administration of recombinant periostin peptide induces cardiomyocyte replacement in a rat infarct model. Here, we report the results of a pre-clinical trial of periostin peptide administration in a porcine myocardial infarction model. We induced myocardial infarction in Yorkshire swine by deploying a coil in the left anterior descending coronary artery. Using a pericardiocentesis approach, we applied periostin fasciclin I-only polypeptide with a Gelfoam-based delivery system for sustained release into the pericardial space 2 days after myocardial infarction. We determined the effect on cardiac function before, 2 days after, 1 month after, and 3 months after initiation of therapy. Control (n=6) and treatment groups (n=7) were comparable in their hemodynamic parameters as well as the extent of myocardial infarction before beginning of therapy (Tab. 1). Ejection fraction, determined by 2D-echocardiography, improved in periostin-treated group at one month after periostin administration (48.0±2.3%) compared to control (38.5±5.0%). Left ventricular catherization showed a significantly increased dP/dt in periostin-treated animals after one month (1709±130 vs. 1355±98 mmHg/s). Similarly after one month cardiac index was increased (114±5.3 vs. 98±10 mL/kg/min). Gain of function in the periostin group was preserved over three months, consistent with a smaller scar volume measured by cMRI and TTC staining (90±11 vs. 127±14 mm3). In summary, minimally invasive application of cardiac regeneration factors is effective and safe. A single dose of periostin peptide induced sustained improvement of cardiac function after myocardial infarction. Overall, inducing myocardial regeneration with recombinant periostin is a promising strategy for the treatment of ischemic heart disease.
Association of Epicardial Adipose Tissue With Progression of Coronary Artery Calcification Is More Pronounced in the Early Phase of Atherosclerosis
Authors: Amir A. Mahabadi, Nils Lehmann, Hagen Kälsch, Tim Robens, Marcus Bauer, Iryna Dykun, Thomas Budde, Susanne Moebus, Karl-Heinz Jöckel, Raimund Erbel, Stefan Möhlenkamp
Journal: JACC. Cardiovascular imaging (2014)